NEW YORK (GenomeWeb) – Quest Diagnostics announced it has completed efforts to refocus its business on diagnostic information services following six divestitures that have yielded $1 billion in proceeds.

The latest divestiture was Quest's sale of Focus Diagnostics' products business to DiaSorin for $300 million in cash. That transaction completed last week.

Quest said it plans to use the money from this transaction to repurchase its common stock. The company has repurchased $2 billion in common stock since 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.